31 completed, 9 terminated, 6 recruiting, 5 active not recruiting. 60 Phase 2, 12 Phase 1, 1 Phase 3.
Follow Peritoneal Cancer: new trials by email Literature Review of Peritoneal Cancer trials Research Report on Peritoneal Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Paricalcitol Versus Pirfenidone for Improving Surgical Resectability in Patients With Peritoneal Cancer Paricalcitol, pirfenidone - Peritoneal (Metastatic) Cancer, Peritoneal Carcinoma | Phase 2 | Not yet recruiting | Patrick Wagner, MD, FACS | 74 | 2026-09-01 | 2026-10-05 |
| Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer Fluzoparib, Bevacizumab, Paclitaxel - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Recruiting | Qilu Hospital of Shandong University | 105 | 2024-11-27 | 2024-12-16 |
| Personalised Timing of Interval Debulking Surgery in Advanced Ovarian Cancer KELIM, Carboplatin plus Paclitaxel, Interval debulking surgery - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Recruiting | The University of Hong Kong | 18 | 2024-05-28 | 2025-07-02 |
| Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery Acute Normovolemic Hemodilution/ANH - Ovarian Cancer, Fallopian Tube Carcinoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 86 | 2024-02-23 | 2026-04-01 |
| An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib Mirvetuximab Soravtansine-gynx, Olaparib - Ovary Cancer, Peritoneal Cancer | Phase 2 | Recruiting | University of Colorado, Denver | 53 | 2023-10-03 | 2026-07-13 |
| Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer Carboplatin - Ovarian Cancer, Relapsed Ovarian Cancer | Phase 2 | Recruiting | University College, London | 80 | 2023-05-24 | 2024-04-12 |
| A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer KAND567, Carboplatin - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 1 / Phase 2 | Completed | Novakand Pharma AB | 18 | 2023-04-26 | 2025-06-08 |
| ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer ZEN003694, Talazoparib - Ovarian Cancer, Peritoneal Cancer | Phase 2 | Recruiting | Alexander B Olawaiye, MD | 33 | 2023-04-21 | 2026-06-18 |
| A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy Allocetra-OTS, Nivolumab, Tislelizumab - Solid Tumor, Peritoneal Metastases | Phase 1 / Phase 2 | Terminated | Enlivex Therapeutics RDO Ltd. | 14 | 2022-11-15 | 2024-04-17 |
| A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. Oregovomab, Niraparib - Recurrent Ovarian Cancer, Recurrent Epithelial Cancer of Ovary | Phase 2 | Active not recruiting | CanariaBio Inc. | 10 | 2022-07-25 | 2026-04-03 |
| Body Surface Area-based vs Concentration-based Dosing of Cisplatin for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Women With Advanced Ovarian Cancer Cisplatin 100 mg/m2, Cisplatin 40 mg/l - FIGO Stage III Ovarian Cancer, Peritoneal Cancer | Phase 2 | Active not recruiting | The Netherlands Cancer Institute | 40 | 2022-06-15 | 2025-07-20 |
| Preoperative Systemic Therapy for Colorectal Cancer Peritoneal Metastases Preoperative systematic therapy, CRS+HIPEC, Postoperative chemotherapy - Colorectal Neoplasms, Colorectal Cancer | Phase 2 | Unknown | Sun Yat-sen University | 168 | 2022-06-01 | 2022-04-29 |
| BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei Bromelain, Acetylcysteine, Interventional radiology insertion of drain - Pseudomyxoma Peritonei, Peritoneal Cancer | Phase 2 | Unknown | Mucpharm Pty Ltd | 62 | 2022-05-01 | 2022-03-15 |
| Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers Mirvetuximab soravtansine - Ovarian Cancer, Peritoneal Cancer | Phase 2 | Completed | AbbVie | 79 | 2021-10-19 | 2026-01-09 |
| A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRĪ±) ELU001 - Ovarian Cancer, Ovarian Neoplasms | Phase 1 / Phase 2 | Terminated | Elucida Oncology | 79 | 2021-09-13 | 2024-08-07 |
| Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC SG001, Doxorubicin hydrochloride liposome injection - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Unknown | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 126 | 2021-09-01 | 2021-07-30 |
| A Study of Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer Gimatecan - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Unknown | Lee's Pharmaceutical Limited | 46 | 2021-07-01 | 2021-04-19 |
| T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer Ipilimumab, Cyclophosphamid, Fludarabine Phosphate - Metastatic Ovarian Cancer, Metastatic Fallopian Tube Cancer | Phase 1 / Phase 2 | Terminated | Inge Marie Svane | 6 | 2021-04-22 | 2025-08-12 |
| A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum 131 I-omburtamab, WAP-IMRT - Desmoplastic Small Round Cell Tumor, Peritoneal Cancer | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 31 | 2019-07-15 | 2026-07-21 |
| Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer Pembrolizumab - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Completed | University College, London | 20 | 2019-05-16 | 2026-05-20 |
Showing 20 of 60. Sign in to see all of them.
Ovarian Neoplasms (50) · Fallopian Tube Neoplasms (49) · Carcinoma, Ovarian Epithelial (11) · Neoplasms (7) · Recurrence (7) · Peritoneal Neoplasms (3) · Breast Neoplasms (2) · Carcinoma, Endometrioid (2) · Colorectal Neoplasms (2) · Endometrial Neoplasms (2) · Neoplasm Metastasis (2) · Ovarian Diseases (2) · Adenocarcinoma, Mucinous (1) · Carcinoma (1) · Colonic Neoplasms (1)
Neoplasms by Site (57) · Adnexal Diseases (54) · Female Urogenital Diseases (54) · Female Urogenital Diseases and Pregnancy Complications (54) · Genital Diseases (54) · Genital Diseases, Female (54) · Genital Neoplasms, Female (54) · Urogenital Diseases (54) · Urogenital Neoplasms (54) · Endocrine Gland Neoplasms (53) · Endocrine System Diseases (53) · Gonadal Disorders (53) · Neoplasms (52) · Ovarian Diseases (51) · Fallopian Tube Diseases (49)
Carboplatin (13) · Bevacizumab (7) · Paclitaxel (7) · Gemcitabine (6) · pembrolizumab (4) · Nivolumab (3) · Pemetrexed (3) · rucaparib (3) · Cisplatin (2) · Cyclophosphamide (2) · Granulocyte-Macrophage Colony-Stimulating Factor (2) · Hyperthermic Intraperitoneal Chemotherapy (2) · Letrozole (2) · Topotecan (2) · mirvetuximab soravtansine (2)
Dana-Farber Cancer Institute (7) · Memorial Sloan Kettering Cancer Center (4) · M.D. Anderson Cancer Center (3) · University College, London (3) · Eli Lilly and Company (2) · GlaxoSmithKline (2) · The Netherlands Cancer Institute (2) · pharmaand GmbH (2) · AA Secord (1) · AGO Study Group (1) · AbbVie (1) · Alexander B Olawaiye, MD (1) · Bay Area Gynecology Oncology (1) · Benaroya Research Institute (1) · CASI pharmaceuticals, Inc. (1)
United States (41) · Canada (5) · Spain (5) · United Kingdom (5) · Australia (3) · Belgium (3) · Denmark (3) · Netherlands (3) · China (2) · France (2) · Ireland (2) · Israel (2) · Italy (2) · Austria (1) · Germany (1)
Ursula Matulonis, MD (4) · Dennis Chi, MD (2) · Agnieszka Michael, MBBS, PhD (1) · Alexander B Olawaiye, MD (1) · Alexandra R Brandt-Kerkhof, MD (1) · Alvaro Arjona Sanchez, MD (1) · Amit Oza (1) · Angeles A Secord, MD (1) · Arend G Aalbers, MD (1) · Armando Sardi, MD (1) · Beihua Kong (1) · Bradley Corr, MD (1)
PMID 31685558, PMID 35397664, PMID 17161453, PMID 18829088, PMID 19264351, PMID 19819917, PMID 21815133, PMID 22487536, PMID 26119093, PMID 27908594, PMID 27998236, PMID 29799676, PMID 30347019, PMID 31023318, PMID 31194225, PMID 31194228, PMID 32193378, PMID 32247603, PMID 32771276, PMID 33528867, PMID 33941784, PMID 34009291, PMID 34019431, PMID 35170751, PMID 36482193, PMID 37185961, PMID 38760075, PMID 39617145, PMID 39806715, PMID 41044356, PMID 42372745
2009 (1), 2015 (1), 2016 (1)